Expression of a recombinant receptor consisting of the extracellular region of CD64 and the transmembrane and intracellular regions of CD16a was tested in iPSC-NK cells to determine if this higher affinity Fc receptor could cytotoxicity against tumor cells in combination with monoclonal antibody treatment (140). Here, FCGR3A is linked to neoplasm.